Non-specific Effects of Vaccines

African child receiving a vaccination

Project Summary: Non-specific Effects of Vaccines

Vaccines can offer broad protection beyond the diseases that they were meant to target. This is called the non-specific effects of vaccines. Live vaccines, such as smallpox, tuberculosis (BCG), polio, and measles (or MMR) vaccines, can reduce child mortality more than what would be expected by fighting the target disease. Non-live or attenuated vaccines, such as DTP, malaria, and heptatis B vaccine, can have the opposite impact by increasing the chance of unrelated infections.

Scientists also know that females are more affected by these non-specific effects. We can reduce the negative impact of non-live vaccines by simply giving the live vaccine after the non-live vaccine. The signficant health impacts of non-specific effects of vaccines can be used to inform vaccination policies for the best outcomes, especially in low-income countries with high childhood mortality rates. The beneficial effects of live vaccines can also help to address health issues as diverse as COVID-19 and cancer.

  • Childhood mortality is high in many parts of the world, especially in low-income countries. According to UNICEF, in 2021, 1 in 14 children in sub-Saharan Africa died before reaching their fifth birthday—15 times higher than the risk for children born in high-income countries.
  • Vaccinations are a way to protect children – and adults – from particular diseases. However, to increase the positive impact of vaccines the type and timing of the vaccination schedule is critical.
  • Routine vaccinations are a key part of protecting the health of children.
  • Our understanding of the non-specific effects of live vaccines has grown tremendously in the past decade. For example, scientists understand that there is a greater impact of these non-specific effects on females as well as an important vaccine sequence to consider.
  • Updated vaccination policies that take into consideration the positive non-specific effects that live vaccines can have could greatly reduce childhood mortality in low-income regions.
  • More emphasis on studies aimed at leveraging existing vaccines to fight new viruses, such as COVID-19, and other diseases like cancer is needed.
  • The Parsemus Foundation supports research on the non-specific effects of vaccines to improve human health. We supported a clinical trial on the impact of the live MMR (measles, mumps, rubella) vaccine to protect from COVID-19. 
  • The Optimmunize Conference brings together scientists who study the beneficial non-specific effects of vaccines. We supported the 2022 conference and assisted with publicity about their work.

Project Topics

Vaccines 101

Vaccines are given to help your immune system fight off infections and disease. They work by priming the immune system so that it recognizes an intruder virus or bacteria and is able to remove it. The vaccine is a weak or inactive form of the disease and is usually given by an injection. The body sees it as an invader, launches an attack by creating antibodies to the disease to kill it. This usually does not create illness, but prepares the body to recognize the virus. Then, if you are exposed to the disease later, the antibodies remember the disease and defend against it.

We usually think of vaccines as being targeted to a specific disease, like the flu. Some vaccines are killed or inactivated. Other vaccines are live or “attenuated”, meaning that they cannot replicate enough to cause illness in our bodies but can be recognized by the immune system. 

Infographic on How Vaccines Work.
Click to see full size image

Non-specific effects of vaccines

Vaccines may have influences beyond the disease they target. These “non-specific effects” of vaccines can be positive or negative. Some vaccines can be successful in helping the immune system to fight other pathogens besides those it was created to target. Live vaccines often have beneficial effects by fighting non-target diseases. For example, the measles vaccine can also protect against sepsis (a life threatening response to infection). This non-specific effect can be very powerful. Researchers have found that live vaccines for smallpox, tuberculosis (BCG), polio, and measles (or MMR) can actually reduce child mortality, beyond the protection it gives for those diseases. 

On the other hand, non-live (killed) vaccines may have the opposite effect. The non-live vaccines – such as DTP (diptheria-tetanus-pertussis) vaccine, hepatitis B vaccine, inactivated polio vaccine, malaria vaccine, H1N1 influenza vaccine – are effective against the target disease but can increase the chance of unrelated infections.

Studies in low-income countries indicate that these non-live vaccines may increase mortality in children because the increase in pneumonia and sepsis outweighs the benefits of fighting the target disease. 

In high-income countries, where child mortality is lower, similar findings have occurred. For example, a study in Denmark found that hospitalization of children for unrelated infections was reduced by recent live measles vaccination. And the non-specific effects of vaccines occurs in adults as well. A randomized placebo-controlled human challenge study found that adults vaccinated with the tuberculosis vaccine were protected against an experimental infection.

Females are affected more by non-specific effects

The non-specific effects of vaccines is greater in females than males. This applies to both protective effects of live vaccines and detrimental effects of non-live vaccines. In Africa, non-live vaccination for malaria was found to double mortality rates in girls. But the non-specific effects of live tuberculosis vaccine had greater beneficial effects on mortality for girls than for boys.

Timing is important

How can we reduce the negative impact of non-live vaccines? Luckily, scientists found that the most recent vaccine given has the strongest non-specific effects. So, to reduce the negative effects of non-live vaccines, a live vaccine can be given after the non-live vaccine. In Denmark, children who were given the live measles, mumps and rubella vaccine after non-live vaccines had a lower rate of hospital admissions for any infections. In the U.S. there was a lower risk of non-target disease hospitalizations in children whose last vaccine received was live compared with inactivated vaccine, as well as concurrent receipt compared with inactivated vaccine

A call for improving the vaccine strategy for newborns

To gain the most positive impact of the non-specific effects of live vaccines, it is important to consider the sequence of vaccination schedules. Live vaccines are usually associated with beneficial overall health effects while some non-live vaccines are associated with poor outcomes. The negative effect of non-live vaccines can be reduced by giving the live vaccine last. 
  • All children in Africa should receive the tuberculosis vaccine at birth to boost the infant’s immune system, which can reduce neonatal mortality by 33%.
  • Oral polio vaccine should not be phased out. This live vaccine has helped to reduce child mortality in low-income countries.
  • Children should be given a live vaccine shortly after receiving non-live vaccines. For example giving the measeles (live) vaccine after the DTP (non-live diptheria, tetanus, pertussis) vaccine.

By simply changing the vaccination policies as to the sequence and types of vaccinations given to children in low-income countries, it is estimated that approximately 1 million lives could be saved each year. These same concepts could also improve outcomes for children in mid- and high-income countries.

The way vaccines are tested, approved, and regulated should also consider non-specific effects to enhance the positive impacts on overall health (see this publication for specific suggestions).

Trained innate immunity and the benefits of attenuated vaccines

For those wanting more details on how a vaccine can have non-specific effects, we need to introduce the concept of “trained innate immunity”.  Trained immunity refers to the ability of the innate immune system to form immune memory and provide long-lasting protection against foreign invaders. Basically, a vaccine kicks the immune system into high gear so it is better able to fight many disease organisms, and therefore provide broader protection.

This process involves changing the innate immune cells by internal or external attacks (such as by a vaccine or virus), resulting in myeloid cells being metabolically and epigenetically reprogrammed. The cells return to a non-activated state but then respond if challenged again later.

Infographic on Trained Immunity
Click to see full size image

Definition: epigenetic reprogramming means that environmental factors such as diet, infectious disease, or vaccination can influence how the genes of a person are expressed (whether a specific gene is turned on or turned off) without changing the actual DNA sequence of the genes themselves.

Live viral and bacterial vaccines (such as tuberculosis, measles, oral polio, and influenza) have been shown to induce trained immunity with protection against non-target diseases. See this article for more details.

What is the future for trained innate immunity and beneficial non-specific effects?

Certainly the timing and sequence of vaccines can provide non-specific protection against diseases in newborns (see above). Scientists also believe that we can train the immune system to battle particular diseases. 
The concept of trained innate immunity has also been applied to the treatment of COVID-19. One adenovirus-based vaccine (the AstraZeneca ChAdOx1 nCoV-19 vaccine) has been shown to result in trained immunity after just one dose, with immune cells responding to antigens unrelated to COVID-19. Other recent studies have used existing live vaccines, including the tuberculosis (BCG) vaccine and the measles, mumps, and rubella vaccine, to provide protection from COVID-19 through their non-specific effects. For example, a blinded, controlled, randomized clinical trial found people who had been given the tuberculosis vaccine had significantly less severe COVID-19 symptoms and hospitalization than the placebo group.
Hand in blue boxing glove hits and destroys Covid virus
Some examples would be inducing trained immunity to support cancer treatment. In fact, the tuberculosis BCG vaccine is approved by the FDA in the U.S. to treat bladder cancer, and has been used for lymphoma and melanoma. 
Another promising area to use trained immunity from vaccines is in the treatment of sepsis – an extreme response to infection that can lead to organ failure and death. A study using a mouse model of sepsis found evidence for  the development of trained innate immune protection against sepsis of broad microbial origin after immunization with Candida dubliniensis.
Inhibiting an overly active immune system is also important. Controlling trained immunity may help in chronic inflammatory diseases or after organ transplantation. 

Take Action on Non-specific Effects of Vaccines

Understanding the different types of vaccines and how they work is an important part of healthcare, especially for children. The knowledge we have now about the importance of the scheduling of live attenuated vaccines can help to create policies that enable the most positive impact of non-specific effects. 

Video: Christine Stabell-Ben “How vaccines train the immune system in ways no one expected” TEDxAarhus 2018.

Podcast: “Vaccines: A tale of the unexpected” BBC HealthCheck Mar 1, 2023.

Bandim Health Project

Aaby P, Netea MG, Benn CS. (2023).  Beneficial non-specific effects of live vaccines against COVID-19 and other unrelated infections. Lancet Infect Dis  23(1): e34–e42. (Full text)

Aaby P, Benn CS, Flanagan KS, et al. (2020). The non-specific and sex-differential effects of vaccines. Nat Rev Immunol 20(8): 464–470. (Full text)

Arts RJW,  Moorlag SJCFM, Novakovic B, et al. (2018). BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 10;23(1):89-100.e5. (Full text)

Bardenheier BH,  McNeil MM, Wodi P, et al. (2017). Risk of non-targeted infectious disease hospitalizations among U.S. children following inactivated and live vaccines, 2005–2014. Clin Infect Dis 65(5):729-737. (Full text)

Benn CS, Fisker AB, Rieckmann A, et al. (2020). Vaccinology: time to change the paradigm? Lancet Infect Dis 20(10):e274-e283. (Abstract)

Benn CS, Amenyogbe N, Björkman A, et al. (2023). Implications of non-specific effects for testing, approving, and regulating vaccines. Drug Safety 46:439–448. (Full text)

Fedrizzi EN, Girondi JBR, Sakae TM, et al. (2022). Efficacy of the measles-mumps-rubella (MMR) vaccine in the reducing the severity of Covid-19: An interim analysis of a randomised controlled clinical trial. J Clin Trials 12(15) No: 1000004. (Full text)

Klein SL, Shann F, Moss WJ, et al. (2016). RTS,S malaria vaccine and increased mortality in girls. ASM Journals mBio 7(2). (Full text)
Moorlag SJCF, van Deuren RC, van Werkhoven CH, et al. (2020). Safety and COVID-19 symptoms in individuals recently vaccinated with BCG: a retrospective cohort study. Cell Rep Med 25;1(5):100073. (Full text)

Murphy DM,  Cox DJ, Connolly SA, et al. (2023).Trained immunity is induced in humans after immunization with an adenoviral vector COVID-19 vaccine.   J Clin Invest 133(2):e162581. (Full text)

Netea MG, Domínguez-Andrés J, Barreiro LB, et al. (2020). Defining trained immunity and its role in health and disease. Nat Rev Immunol 20(6): 375–388. (Full text)

Omar M,  Muhsen K. (2021). A narrative review of nonspecific effects of pediatric vaccines on child mortality and morbidity. Hum Vaccin Immunother 17(12): 5269–5283. (Full text).

Schaltz-Buchholzer F, Berendsen M, Roth A, et al. (2020). BCG skin reactions by 2 months of age are associated with better survival in infancy: a prospective observational study from Guinea-Bissau. BMJ Glob Health 5(9):e002993. (Full text)

Sinha S,  Ajayababu A, Thukral H, et al. (2022). Efficacy of Bacillus Calmette–Guerin (BCG) caccination in reducing the incidence and severity of COVID-19 in high-risk population (BRIC): a Phase III, multi-centre, quadruple-blind randomised control trial. Infect Dis Ther 11:2205–2217. (Full text)

Sørup, Benn CS, Poulsen A, et al. (2014). Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. JAMA 311(8):826-35. (Full text)

Yamazaki-Nakashimada MA, Unzueta U, Gámez-González B,  et al. (2020).  BCG: a vaccine with multiple faces. Hum Vaccin Immunother 16(8). (Full text)

Human Health News

We’re sorry, you are not eligible for the nationwide COVID-OUT or ACTIV-6 studies, but you may be eligible for other federal trials:

And if you don’t find a match there, this slightly more complex clinical trials finder includes studies sponsored by companies as well:

Trials Today